Business
CEO Statement to Shareholders
BELLEVUE, WASHINGTON / ACCESS Newswire / February 2, 2026 /Reaffirming Strategic Execution and Long-Term Value Creation As the compliance deadline under the minimum bid requirement of NASDAQ approaches, we recognize that market volatility and uncertainty ...
About this update from Osr Holdings, Inc.
[{"type":"text","content":"BELLEVUE, WASHINGTON / ACCESS Newswire / February 2, 2026 / Reaffirming Strategic Execution and Long-Term Value Creation","length":120,"tagName":"p"},{"type":"text","content":"As the compliance deadline under the minimum bid requirement of NASDAQ approaches, we recognize that market volatility and uncertainty can weigh on investor sentiment. Periods like this often test confidence, particularly for innovation-driven companies that are building long-term value rather than optimizing for short-term optics.","length":333,"tagName":"p"},{"type":"text","content":"I want to take this opportunity to reaffirm that the fundamentals of OSR Holdings, Inc. remain strong, and that the management team is firmly focused on executing against clearly defined value-creating milestones.","length":213,"tagName":"p"},{"type":"text","content":"Progress on VXM01 Licensing","length":27,"tagName":"p"},{"type":"text","content":"Our Swiss biotech subsidiary, Vaximm AG, continues to make solid progress toward finalizing the global licensing transaction for its lead asset, VXM01. Based on the Binding Term Sheet recently executed with BCM Europe AG, the contemplated transaction structure includes:","length":270,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Up to USD 815 million in development, regulatory, and commercial milestones","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"USD 30 million upfront consideration, consisting of USD 15 million in cash and USD 15 million in digital assets","length":111,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":186,"olType":false},{"type":"text","content":"While the definitive agreement remains subject to customary conditions, diligence, and final documentation, discussions are advancing constructively and in line with the economic framework already disclosed. We view this potential licensing transaction as a meaningful validation of VXM01's platform value and of OSR Holdings' hub-and-spoke biotech strategy.","length":366,"tagName":"p"},{"type":"text","content":"Strategic Review of Medical Device Platform Merger","length":50,"tagName":"p"},{"type":"text","content":"In parallel, we are encouraged by the ongoing strategic discussions between our two medical device subsidiaries, RMC and Woori IO. Management teams from both companies are actively working toward...